The latest blockbuster drugs will be available on the Pharmaceuticals Actuary’s website in February and the Government will begin negotiations for the next generation of drugs, which is the process of developing a generic drug that is more widely available and has lower price.

This new drug category will also include a new class of drugs for chronic diseases.

It comes after the Government launched a two-year clinical trial in 2015 to test the efficacy of the drug clomiphene citrate, a generic of the company GlaxoSmithKline’s carboplatin, in patients with type 1 diabetes, which has now been used for the first time for more than a decade.

The trial was to be conducted in conjunction with Glaxosmear’s Phase 2b clinical trial.

In February, the Government announced it would make a decision on the next drugs from that trial by the end of March.

The Government is also planning to introduce a new clinical trial, for Type 1 diabetes and type 2 diabetes, in 2019.

This trial is designed to determine whether there is a need to continue the development of a new generation of insulin-like growth factor-1 (IGF-1) drug in the context of the ongoing development of the next wave of generic drugs.

The aim is to continue to develop the next gen drug in a way that will allow for the development and commercialisation of a more affordable and effective insulin-related therapy, which will help to reduce the cost of diabetes and the incidence of type 2 disease, and also help improve patient quality of life.